Epidemiology & Risk Factors
Demographics : F > M (~9:1 female predominance); peak incidence in 20s–30s.Genetic Risk : Associated with HLA-DR4 and HLA-DR1 .Etiology : Autoimmune-mediated systemic overlap syndrome combining features of SLE , Systemic Sclerosis (SSc) , and Polymyositis (PM) . c
Clinical Features
Vascular :
Raynaud phenomenon : Earliest and most common manifestation (>90%).
Dermatologic :
“Puffy fingers” / swollen hands (“sausage digits”) progressing to sclerodactyly.Malar-like erythema, discoid plaques, or heliotrope-like eruptions.
Musculoskeletal :
Symmetrical, non-erosive polyarthritis or polyarthralgias.
Proximal muscle weakness and tenderness (myositis).
Pulmonary :
Exertional dyspnea, nonproductive cough, chest pain (pleuritis).
Signs of Pulmonary Arterial Hypertension (PAH) : Loud P2, right ventricular heave, elevated JVP.
Gastrointestinal :
Esophageal dysmotility, dysphagia, and severe GERD (SSc-like feature).
Diagnosis
Initial / Screening :
ANA : Positive in >95% (typically high titer with speckled pattern).
Confirmatory / Pathognomonic :
High-titer Anti-U1-RNP antibodies : Mandatory diagnostic criterion (absence virtually excludes MCTD). c
Key Labs :
Muscle Enzymes : ↑ CK and ↑ Aldolase (reflects active myositis).Inflammatory Markers : ↑ ESR and ↑ CRP.CBC : Cytopenias (anemia of chronic disease, leukopenia, thrombocytopenia).Autoantibody Differentiation :
Negative or low titers of Anti-dsDNA and Anti-Sm (suggests SLE if high).
Negative or low Anti-Scl-70 / Anti-centromere (suggests pure SSc).
Negative Anti-Jo-1 (suggests pure PM/DM).
Imaging & Functional Testing :
High-Resolution CT (HRCT) Chest : Screens for Interstitial Lung Disease (ILD) (ground-glass opacities, bibasilar fibrosis).Pulmonary Function Tests (PFTs) : Restrictive pattern (↓ FVC, ↓ TLC) with ↓ DLCO .Transthoracic Echocardiogram (TTE) : Initial screen for PAH (estimated ↑ RVSP).Right Heart Catheterization (RHC) : Gold standard to confirm PAH (mPAP > 20 mmHg with normal wedge pressure).
Differential Diagnostics
Systemic Lupus Erythematosus (SLE) :
Diff by prominent lupus nephritis, hypocomplementemia (↓ C3/C4), and positive Anti-dsDNA / Anti-Smith antibodies.
Systemic Sclerosis (SSc) :
Diff by severe diffuse cutaneous sclerosis, higher risk of scleroderma renal crisis, and positive Anti-Scl-70 or Anti-centromere antibodies without high-titer anti-U1-RNP.
Polymyositis / Dermatomyositis :
Diff by absence of SSc/SLE overlap features, cutaneous pathognomonic signs (Gottron papules, heliotrope rash), and positive Anti-Jo-1 or Anti-Mi-2 .
Rheumatoid Arthritis (RA) :
Diff by classic erosive symmetrical joint destruction on radiography, positive Anti-CCP , and absence of Raynaud or esophageal dysmotility.
Undifferentiated Connective Tissue Disease (UCTD) :
Diff by non-specific autoimmune manifestations that fail to fulfill criteria for defined CTDs and lack high-titer Anti-U1-RNP.
Management
Raynaud Phenomenon :
First-line: Cold avoidance, smoking cessation, and Dihydropyridine CCBs (e.g., Amlodipine, Nifedipine).
Refractory / Severe: Phosphodiesterase-5 (PDE-5) inhibitors (e.g., Sildenafil) or topical nitrates.
Mild Disease (Arthralgias, Mild Cutaneous Symptoms) :
First-line: NSAIDs , low-dose oral glucocorticoids , and Hydroxychloroquine (HCQ) .
Moderate Disease (Myositis, Pleuritis, Pericarditis) :
First-line: Moderate-to-high dose systemic glucocorticoids (Prednisone 0.5–1 mg/kg/day).
Maintenance / Steroid-sparing: Methotrexate (MTX) or Azathioprine (AZA) .
Severe / Organ-Threatening Disease (Severe ILD, Neurologic, Renal) :
First-line: IV pulse Methylprednisolone combined with Mycophenolate Mofetil (MMF) or Cyclophosphamide .
Refractory: Rituximab .
Pulmonary Arterial Hypertension (PAH) :
Targeted vasodilators: Endothelin receptor antagonists (e.g., Ambrisentan, Bosentan), PDE-5 inhibitors (e.g., Tadalafil), and Prostacyclin analogues (e.g., Epoprostenol).
Complications
Pulmonary Arterial Hypertension (PAH) : Leading cause of disease-related mortality .Interstitial Lung Disease (ILD) : Progressive pulmonary fibrosis causing respiratory failure.Cardiac Complications : Pericarditis, myocarditis, conduction block, and heart failure.Gastrointestinal : Refractory esophageal strictures and aspiration pneumonia secondary to dysmotility.Iatrogenic / Immunosuppression : Opportunistic infections, osteoporosis, and steroid-induced avascular necrosis.